The estimated Net Worth of Elona Kogan is at least 571 千$ dollars as of 6 February 2024. Ms Kogan owns over 12,684 units of Seer stock worth over 439,759$ and over the last 6 years she sold SEER stock worth over 131,456$.
Ms has made over 4 trades of the Seer stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 12,684 units of SEER stock worth 20,041$ on 6 February 2024.
The largest trade she's ever made was selling 12,684 units of Seer stock on 6 February 2024 worth over 20,041$. On average, Ms trades about 3,500 units every 61 days since 2019. As of 6 February 2024 she still owns at least 273,142 units of Seer stock.
You can see the complete history of Ms Kogan stock trades at the bottom of the page.
Elona Kogan J.D., Esq. is the Gen. Counsel & Sec. at Seer.
Ms Esq is 51, she's been the Gen. Counsel & Sec. of Seer since . There are 3 older and 1 younger executives at Seer. The oldest executive at Seer, Inc. is David R. Horn, 53, who is the Exec. VP & Chief Financial Officer.
Elona's mailing address filed with the SEC is C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY, CA, 94065.
Over the last 7 years, insiders at Seer have traded over 150,878,393$ worth of Seer stock and bought 1,798,420 units worth 33,507,980$ . The most active insiders traders include Omid Farokhzad、Terrance Mcguire、Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of 227,813$. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth 21,554$.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Seer executives and other stock owners filed with the SEC include: